The American Journal of Psychiatry
|Edited by||Ned H. Kalin|
American Journal of Insanity
American Psychiatric Association (United States)
|ISO 4||Am. J. Psychiatry|
The American Journal of Psychiatry is a monthly peer-reviewed medical journal covering all aspects of psychiatry, and is the official journal of the American Psychiatric Association. The first volume was issued in 1844, at which time it was known as the American Journal of Insanity. The title changed to the current form with the July issue of 1921.
According to the Journal Citation Reports, the journal has a 2020 impact factor of 18.112.
Several complaints, including legal cases, have charged The American Journal of Psychiatry with being complicit in pharmaceutical industry corruption of clinical trial results. In a Department of Justice case against Forest Pharmaceuticals, Forest pleaded guilty to the charges of misbranding the drug Celexa (citalopram). The Complaint in Intervention clearly identifies a 2004 ghostwritten article published in ‘’The American Journal of Psychiatry in the names of Wagner et al. as a part of this illegal marketing of Celexa for pediatric depression.
- ^ "About The American Journal of Psychiatry". American Psychiatric Association. 2021. Retrieved 2021-07-12.
- ^ "American Journal of Psychiatry". 2020 Journal Citation Reports. Web of Science (Science ed.). Clarivate. 2021-06-30.
- ^ Jureidini, Jon N.; Amsterdam, Jay D.; McHenry, Leemon B. (2016). "The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance". International Journal of Risk & Safety in Medicine. 28 (1): 33–43. doi:10.3233/JRS-160671. PMID 27176755.
- ^ United States v Forest Pharmaceuticals, Plea Agreement, September 15, 2010
- ^ Wagner, K. D.; Robb, A. S.; Findling, R. L.; Jin, J.; Gutierrez, M. M.; Heydorn, W. E. (2004). "A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents". The American Journal of Psychiatry. 161 (6): 1079–83. doi:10.1176/appi.ajp.161.6.1079. PMID 15169696.
- ^ United States v Forest Pharmaceuticals, Complaint in Intervention p. 17. section 60.